Olema Pharmaceuticals amends loan facility, ups potential borrowing to $100M, extends maturity to 2028

Olema Pharmaceuticals, Inc.

Borrowing capacity increased from $50M to up to $100M with $25M immediately available.
Additional $25M available upon milestone: execution of first line pivotal Phase 3 trial of palazestrant with ribociclib.
Further $50M may be available at bank's discretion; maturity extended 11 months to July 1, 2028.
No funds drawn under the loan agreement to date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.